$6.56
▼ $-0.39
(-5.61%)
Vol 441K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$272.7M
ROE
-26.4%
D/E
0.00
Beta
0.00
52W
$1–$5
Wall Street Consensus
18 analysts · Apr 20269
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
94.4%
Buy Rating
Price Chart
Similar Stocks
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
GLSI
Greenwich Lifesciences Inc
$291.1M
PALI
Palisade Bio Inc
$350.2M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
ORGO
Organogenesis Holdings Inc
P/E 654.1
$657.4M
NBP
NovaBridge Biosciences
$458.9M
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.20 | $-0.26 | $-0.06 |
| Sep 2025 | $-0.15 | $-0.19 | $-0.04 |
| Jun 2025 | $-0.19 | $-0.13 | +$0.06 |
| Mar 2025 | $-0.15 | $-0.31 | $-0.16 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$8.4M | -$20.8M | -$8.7M | -$12.9M | -$17.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -23.1% | -23.1% | -23.1% | -23.1% | -26.4% | -26.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 14.08 | 14.08 | 14.08 | 14.08 | 18.38 | 18.38 |
Key Ratios
ROA (TTM)
-25.6%
P/B
0.6
EPS (TTM)
$-0.75
52W High
$5.05
52W Low
$1.05
$1.05
52-Week Range
$5.05
Financial Health
Free Cash Flow
-$15.6M
Net Debt
-$35.1M
Cash
$35.7M
Total Debt
$541K
As of Dec 31, 2025
How does CLYM compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CLYM valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0.6
▼
76%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CLYM profitability vs Biotechnology peers
ROE
-26.4%
▲
61%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-25.6%
▲
45%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CLYM financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
18.4
▲
314%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.0
▼
100%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CLYM fundamentals radar
CLYM
Peer median
Industry
CLYM profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CLYM vs peers: key metrics
Latest News
No related news yet